Nuvectis Pharma, INC 8-K filings

Nuvectis Pharma reported Q2 2026 results, highlighting the in-licensing of two promising drug candidates, the first global approval for ciprocopan in China, and a successful $115 million follow-on offering.

Nuvectis Pharma announced the pricing of its public offering of common stock, raising approximately $100 million in gross proceeds.

Nuvectis Pharma, Inc. has suspended its at-the-market stock offering and reduced the maximum amount available for future sales to $5 million.

Nuvectis Pharma reported Q1 2026 results, highlighting continued patient enrollment in its NXP900 Phase 1b trial and preclinical data supporting combination therapy.

Nuvectis Pharma, Inc. announced its financial results for the year ended December 31, 2025, highlighting progress in its NXP900 clinical development program and a strengthened cash position.

Nuvectis Pharma reports Q3 2025 financial results and business highlights, including the initiation of its NXP900 Phase 1b program and a strong cash position.

Nuvectis Pharma, Inc. announced the appointment of seasoned biotech executive Juan Sanchez, MD, to its Board of Directors, bringing extensive industry, capital markets, and medical expertise.

Nuvectis Pharma reports successful Phase 1a completion for NXP900, with Phase 1b imminent, and strengthens its cash position to $39 million, extending its runway into late 2027.

Nuvectis Pharma, Inc. announced that all proposals, including the election of a Class III director and the ratification of its independent auditor, were approved by stockholders at its 2025 Annual Meeting held on June 12, 2025.

Nuvectis Pharma establishes a new at-the-market offering program to sell up to $60 million of its common stock through Leerink Partners LLC.

Nuvectis Pharma announces first quarter 2025 financial results, highlighting positive clinical data for NXP900 and a strengthened cash position extending into the first quarter of 2027.

Nuvectis Pharma announces its 2024 financial results, highlights progress in clinical trials for NXP800 and NXP900, and reports a follow-on offering extending cash runway into 2027.

Nuvectis Pharma has priced its public offering of common stock at $5.00 per share, expecting gross proceeds of $13.5 million, and the underwriter has fully exercised its option to purchase additional shares.

Nuvectis Pharma announced its third quarter 2024 financial results and provided updates on its clinical programs, including progress on NXP800 and NXP900.

Nuvectis Pharma has been granted Orphan Drug Designation by the FDA for its drug candidate NXP800, targeting a specific subset of ovarian, fallopian tube, and primary peritoneal cancers.

Nuvectis Pharma announced its second quarter 2024 financial results, highlighting progress in clinical trials for NXP800 and NXP900, and a decrease in net loss compared to the same period last year.

Nuvectis Pharma successfully held its 2024 Annual Meeting, with all proposals approved, including the election of Class II directors and the ratification of the company's auditor.

Nuvectis Pharma reported encouraging preliminary data from its NXP800 Phase 1b study and provided a financial update for the first quarter of 2024.

Nuvectis Pharma announced its 2023 financial results, highlighting progress in clinical trials for NXP800 and NXP900, and anticipates multiple data readouts in 2024.